Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong partnership with Illumina, strategic capital allocation, and cost reductions are positive. However, declining revenues, gross margins, and CFO departure pose risks. The Q&A reveals management's limited transparency and reliance on a few large accounts, adding uncertainty. The share repurchase program offers some support, but overall, the mixed signals and lack of specific guidance adjustments suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue (Q2 2024) $37 million, down 23% year-over-year; primarily impacted by project delays in SomaScan assay services.
Revenue (First Half 2024) $83 million, down 11% year-over-year; driven by timing of orders from large pharma accounts.
Product Revenue (Q2 2024) $22 million, down 10% year-over-year; impacted by economic pressures on instrument orders.
Product Revenue (First Half 2024) $46 million, up 6% year-over-year; driven by traction in SomaScan assay kits.
Instrument Revenue (Q2 2024) $16 million, down 27% year-over-year; affected by constrained customer funding cycles.
Instrument Revenue (First Half 2024) $31 million, down 20% year-over-year; correlated with extended sales cycles.
Service Revenue (Q2 2024) $14 million, down 37% year-over-year; primarily due to a decline in SomaScan-related business.
Service Revenue (First Half 2024) $36 million, down 25% year-over-year; driven by reduced SomaScan service volumes.
Gross Margin (Q2 2024) 45%, down from 53% year-over-year; impacted by lower capacity utilization and strategic decisions on instrument upgrades.
Gross Margin (First Half 2024) 51%, down from 53% year-over-year; similar headwinds as Q2.
Operating Expenses (Q2 2024) Just under $48 million, down 19% year-over-year; reflecting ongoing cost reduction initiatives.
Operating Expenses (First Half 2024) Just under $96 million, down 27% year-over-year; driven by operational efficiency measures.
Cash Position (End of Q2 2024) $396 million; provides a competitive advantage in a constrained capital environment.
Adjusted Operating Cash Burn (Q2 2024) $28 million, down 7% year-over-year; improved sequentially from the first quarter.
Share Repurchase (First Half 2024) Purchased approximately 15.4 million shares for about $41 million; average repurchase price of $2.66 per share.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SomaScan Assay: SomaScan and its proprietary aptamer technology is a leading proteomics platform with tremendous upside. Partnership with Illumina for commercial release in the first half of 2025.
Single SOMAmer Reagents: Exploring new models to sell SomaScan with a lower plex, more cost-effective model and single SOMAmer reagents, aiming for a minimal viable product launch this fall.
Multi-omics-as-a-service: Deploying Multi-omics-as-a-service offering leveraging SomaScan and CYTO combined technology platforms to expand lab services business.
Revenue Guidance: Revising revenue guidance to $170 million to $175 million for the full year 2024 due to weaker-than-anticipated second quarter revenue.
Market Dynamics: Current market dynamics are creating opportunities for strategic M&A to drive additional scale, diversification, and shareholder value.
Cost Reduction Target: Accelerated $80 million cost reduction target to the end of 2024, a year ahead of plan.
Operating Expense Reduction: Operationalized $60 million in annualized operating expense reductions, with a commitment to accelerate the remaining $20 million target by the end of the year.
Leadership Changes: Jeff Black, CFO, is leaving; Alex Kim will take on the interim CFO role, and Sean MacKay appointed as Chief Business Officer.
Focus on Integration: Focus on early integration of SomaLogic has accelerated synergy realization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Guidance Revision: The company revised its revenue guidance to $170 million to $175 million for the full year 2024 due to weaker-than-anticipated second quarter revenue, primarily attributed to contract delays in SomaScan services and a down year-over-year instrument revenue.
Economic Pressures: The company is facing ongoing economic pressures that have led to a restricted capital purchasing environment, affecting instrument orders and overall revenue.
Project Delays: SomaScan assay services experienced project delays, particularly in the EMEA region, which significantly impacted revenue.
Sales Cycle Extension: The sales cycle has extended across the portfolio, indicating a longer timeline for revenue realization.
Operating Cost Management: Despite challenges, the company has successfully reduced non-GAAP operating expenses by over $30 million, or 27%, compared to the first half of 2023.
Cash Flow and Burn Rate: The company reported a cash burn of about $28 million, which, while improved, indicates ongoing cash outlays for merger-related and restructuring activities.
Leadership Transition: The departure of CFO Jeff Black may pose a risk during the transition period, although the company has a plan in place for succession.
Market Dynamics: The current market dynamics are creating opportunities for strategic M&A, but also present risks associated with integration and execution.
Gross Margin Pressure: Non-GAAP gross margin decreased to 45% in the second quarter, down from 53% in 2023, due to lower capacity utilization and strategic decisions impacting costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cost Reduction Target: Accelerated the $80 million cost reduction target to the end of 2024, a year ahead of plan.
SomaScan Partnership: Partnering with Illumina for the commercial release of SomaScan assay on Illumina's NovaSeq platform in the first half of 2025.
Multi-omics-as-a-service Offering: Deploying Multi-omics-as-a-service to leverage SomaScan and CYTO technology platforms.
M&A Strategy: Active in strategic M&A to drive scale, diversification, and shareholder value.
Revenue Guidance: Revised revenue guidance for 2024 to $170 million to $175 million.
Adjusted EBITDA Breakeven: Committed to achieving breakeven adjusted EBITDA for the full year 2026.
Cash Position: Ended Q2 2024 with nearly $400 million in cash to support strategic initiatives.
Operating Expense Reduction: Operationalized $60 million in annualized operating expense reductions, targeting an additional $20 million by year-end.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The Board approved a new share repurchase program of up to $50 million. Through the first half of 2024, approximately 15.4 million shares (about 4% of common outstanding shares) were purchased for about $41 million in cash at an average repurchase price of $2.66 per share. The buyback plan was suspended on May 2nd.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you just talk about the remainder of the bridge on the cut in terms of products for service, proteomics versus genomics? What are you assuming for each of those for the year now?
A:We don't -- we've not broken out the components, either by segment or by product line in terms of what the back half looks like. But we are seeing encouraging signs of an uptick in some of the large pharma accounts.
Q:Can you talk about visibility or clarity around the step-up in the second half?
A:We have very good visibility to the second half, hence, the updated guidance.
Q:Just to be clear, that's kind of timing-related revenue and it didn't really go out or do you still expect to kind of recoup that over the coming quarters?
A:Yes. So, mostly timing here on the forecasting miss, we are overly reliant on a few big customers.
Q:How should we be thinking about the top line from here?
A:We do see very healthy growth across our proteomics portfolio, which is about 80% of the revenue.
Q:Can you speak a little bit more to like what the -- any components?
A:The updated guidance is what we have visibility today.
Q:Anything you could speak to about the relative trends in the quarter and how they came in and kind of how you're thinking about the back half of those?
A:The consumables spend is -- consumer revenue, if you include the authorized side in the way I look at it, we're actually flat year-over-year.
Q:What was the genomics in the quarter in terms of revenue?
A:It's down versus 6% in the first half of the year.
Q:On the SomaLogic decline year-over-year, is that business that can be recouped or no?
A:Yes, they will come later, but all projects are shifted out, hence the takedown of the guide.
Q:Review of Unclear Management Responses
A:Management did not provide specific breakdowns of revenue by segment or product line for the second half, which left some questions about the clarity of their guidance. Additionally, while they mentioned encouraging signs in large pharma accounts, they did not provide specific data or details on how these would impact revenue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO
Egholm President
Illumina
Instruments consumables
SomaScan assay
SomaScan service
action
assay service
basis technology
breakeven
bridge
capital
color
comp
component
consumables environment
contract
cost reduction
cut
decision
decrease
expense reduction
family
finance
forecasting
guide
handful
home
industry
kind
offering
people
pharma account
place
project
reduction forma
sale cycle
share
sign
th
transition
uptick
vision
LAB Transcript
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Unknown5-6
The earnings call presents mixed signals: strong cost management and cash position are positive, but declining revenues, gross margins, and ongoing cash burn are concerning. The optimistic guidance and strategic partnerships offer potential upside, yet uncertainties in revenue timing and market conditions temper expectations. The Q&A session reveals cautious optimism but lacks clarity on key issues. Overall, the stock price is likely to remain neutral in the short term as positive strategic moves are counterbalanced by financial and operational challenges.
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings report highlights several negative factors: a 9% revenue decline, significant drops in instrument and lab services revenue, and decreased gross margins. Despite improved cost management and strong consumables growth, the overall financial performance is weak. The lack of a shareholder return plan and unclear management guidance further contribute to uncertainty. The Q&A session reveals limited confidence in market recovery and no specific guidance on cash burn. The positive Illumina partnership is overshadowed by broader financial challenges, leading to a likely negative stock reaction.
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed picture. While there are positive developments like cost synergies and reduced cash burn, revenue decline and reliance on major customers pose risks. The partnership with Illumina and growth in consumables are positives, but weak instrument sales and cautious guidance for China offset these gains. The Q&A highlights management's cautious stance and lack of specific guidance, which could concern investors. Given these mixed signals, the stock price is likely to remain neutral in the short term.
Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong partnership with Illumina, strategic capital allocation, and cost reductions are positive. However, declining revenues, gross margins, and CFO departure pose risks. The Q&A reveals management's limited transparency and reliance on a few large accounts, adding uncertainty. The share repurchase program offers some support, but overall, the mixed signals and lack of specific guidance adjustments suggest a neutral stock price movement in the short term.
LAB Slides
LAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
